Dynavax Technologies Corporation
0IDA.L
London Stock Exchange15.49
USD
+0.00
- -
Dynavax Technologies Corporation
0IDA.L
(London Stock Exchange)
Recent
price
15.49
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Dynavax Technologies Corporation (Nasdaq: DVAX; 0IDA.L), a commercial-stage biopharmaceutical company headquartered in Emeryville, California and founded in 1996, develops and commercializes innovative vaccines leveraging its proprietary CpG 1018 toll-like receptor 9 agonist adjuvant technology to protect against infectious diseases. The company offers HEPLISAV-B, a two-dose adjuvanted hepatitis B vaccine approved in the United States and European Union for adults 18 years and older to prevent infection from all known hepatitis B virus subtypes; CpG 1018 adjuvant, supplied to partners for use in multiple adjuvanted COVID-19 vaccines, seasonal influenza, universal influenza, plague, shingles and Tdap programs; and an advancing pipeline including a plague (rF1V) vaccine candidate fully funded by the U.S. Department of Defense, a shingles prevention vaccine in Phase 1/2 with data expected in Q3 2025, and other biodefense and immunotherapy candidates such as SD-101. Dynavax operates primarily in the United States with commercial infrastructure supporting hospitals, clinics and government agencies through wholesalers and specialty distributors; it maintains a European office in Düsseldorf, Germany for market access and regulatory engagement, and extends global reach via collaborations and clinical trials across North America, Europe and select international markets. Recent developments include a November 2025 exclusive worldwide license agreement with Vaxart for its Phase 2b oral COVID-19 vaccine program, featuring a $25 million upfront payment, $5 million equity investment, and potential milestones up to $195 million regulatory and $425 million sales plus low-to-mid teens royalties following topline data expected late 2026; a new $30 million U.S. Department of Defense agreement through mid-2027 supporting plague vaccine Phase 2 initiation in Q3 2025; a $100 million share repurchase program announced with Q3 2025 results, half of which was previously executed under a prior authorization; and sustained HEPLISAV-B growth capturing 44% U.S. market share in 2024 with 2025 guidance of $305-325 million in sales.